Evidence map›Paper›PMID 26503325›Full record

ArticleBMC cancer2015

E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.

Kyeong-Su Park, Ju Hee Kim, Hee Won Shin, Kyung-Sook Chung, Dong-Soo Im, Jung Hwa Lim, Cho-Rok Jung

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kyeong-Su ParkGene Therapy Research Unit, KRIBB, Daejeon, Republic of Korea. Park-pksu@equisnzaroo.com.
Ju Hee KimGene Therapy Research Unit, KRIBB, Daejeon, Republic of Korea. Kim-wooahaha@kribb.re.kr.
Hee Won ShinGene Therapy Research Unit, KRIBB, Daejeon, Republic of Korea. Shin-shinhw@kribb.re.kr.
Kyung-Sook ChungGenome research center, KRIBB, Daejeon, Republic of Korea. Chung-kschung@kribb.re.kr.
Dong-Soo ImGene Therapy Research Unit, KRIBB, Daejeon, Republic of Korea. Im-imdongsu@kribb.re.kr.
Jung Hwa LimGene Therapy Research Unit, KRIBB, Daejeon, Republic of Korea. jhwa@kribb.re.kr.
Cho-Rok JungGene Therapy Research Unit, KRIBB, Daejeon, Republic of Korea. crjung@kribb.re.kr.
Korea Research Institute of Bioscience and Biotechnology · KRGenome Research Foundation · KRKorea University of Science and Technology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMissense mutation of VHL gene is frequently detected in type 2 VHL diseases and linked to a wide range of pVHL functions and stability. Certain mutant pVHLs retain ability to regulate HIFs but lose their function by instability. In this case, regulating of degradation of mutant pVHLs, can be postulated as therapeutic method.

methodThe stability and cellular function of missense mutant pVHLs were determine in HEK293T transient expressing cell and 786-O stable cell line. Ubiquitination assay of mutant VHL proteins was performed in vitro system. Anticancer effect of adenovirus mediated shUCP expressing was evaluated using ex vivo mouse xenograft assay.

resultsThree VHL missense mutants (V155A, L158Q, and Q164R) are directly ubiquitinated by E2-EPF UCP (UCP) in vitro. Mutant pVHLs are more unstable than wild type in cell. Missense mutant pVHLs interact with UCP directly in both in vitro and cellular systems. Lacking all of lysine residues of pVHL result in resistance to ubiquitination thereby increase its stability. Missense mutant pVHLs maintained the function of E3 ligase to ubiquitinate HIF-1α in vitro. In cells expressing mutant pVHLs, Glut-1 and VEGF were relatively upregulated compared to their levels in cells expressing wild-type. Depletion of UCP restored missense mutant pVHLs levels and inhibited cell growth. Adenovirus-mediated shUCP RNA delivery inhibited tumor growth in ex vivo mouse xenograft model.

conclusionThese data suggest that targeting of UCP can be one of therapeutic method in type 2 VHL disease caused by unstable but functional missense mutant pVHL.

Indexed as

ProteolysisAnimalsFemaleHEK293 CellsHeLa CellsHumansMiceMice, Inbred BALB CMice, NudeMutation, MissenseProtein StabilityUbiquitinUbiquitin-Conjugating EnzymesVon Hippel-Lindau Tumor Suppressor ProteinXenograft Model Antitumor AssaysUbe2S protein, humanUbiquitinUbiquitin-Conjugating EnzymesVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID26503325
PMCPMC4624580
OpenAlexW2176960255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.